Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer
G Grazia(Breast Cancer Research Foundation), Federica Martorana(University of Catania), Paolo Vigneri(Humanitas University), Stefania Stella(University of Catania), Michele Massimino(Surgical Specialties (Canada)), Mario Giuliano(Regione Campania), Chiara Conti(National Cancer Institute), Francesco Schettini(Breast Cancer Research Foundation), Sabrina Nucera(University of Catania)
Cited by 5
Related Papers
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268